Hepatitis B Virus Reactivation in a Patient With Resolved Hepatitis B Virus Infection Receiving Maintenance Rituximab for Malignant B-Cell Lymphoma
Authors: Yu Xuan Koo
Journal: Annals of Internal Medicine (2009)

Letters5 May 2009Hepatitis B Virus Reactivation in a Patient With Resolved Hepatitis B Virus Infection Receiving Maintenance Rituximab for Malignant B-Cell LymphomaYu Xuan Koo, Daniel S.W. Tan, MBBS, Iain B. Tan, MBBS, Miriam Tao, MBBS, and Soon Thye Lim, MBBSYu Xuan KooFrom Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, and National Cancer Centre Singapore, Singapore 169610.Search for more papers by this author, Daniel S.W. Tan, MBBSFrom Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, and National Cancer Centre Singapore, Singapore 169610.Search for more papers by this author, Iain B. Tan, MBBSFrom Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, and National Cancer Centre Singapore, Singapore 169610.Search for more papers by this author, Miriam Tao, MBBSFrom Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, and National Cancer Centre Singapore, Singapore 169610.Search for more papers by this author, and Soon Thye Lim, MBBSFrom Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, and National Cancer Centre Singapore, Singapore 169610.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-9-200905050-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: The risk for hepatitis B virus (HBV) reactivation in patients with seemingly resolved infection who are undergoing treatment for cancer remains controversial.Objective: To report a case of HBV reactivation in a patient with seemingly resolved infection who was undergoing lymphoma treatment.Case Report: A 71-year-old man with mantle cell lymphoma had previously resolved hepatitis B virus (HBV) infection, defined as negative HBV surface antigen (HBsAg) with detectable antibody to HBV core antigen (anti-HBc). He had no detectable antibody to HBsAg (anti-HBsAg). Full staging investigations showed multiple enlarged lymph nodes. An excision biopsy of the right axillary lymph node ...References1. Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, et al; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol. 2006;17:1418-23. [PMID: 16766582] CrossrefMedlineGoogle Scholar2. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605-11. [PMID: 19075267] CrossrefMedlineGoogle Scholar3. Koo YX, Tan SW, Tan BH, Quek R, Tao M, Chow WC, et al. Risk of hepatitis B virus (HBV) reactivation and role of anti-viral prophylaxis in lymphoma patients with past HBV infection (HBV antigen negative but anti-hepatitis B core antibody positive) receiving chemo-immunotherapy blood [Abstract]. ASH Annual Meeting Abstracts. 2008;112:3768. Google Scholar4. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy [Letter]. Haematologica. 2008;93:951-2. [PMID: 18515881] CrossrefMedlineGoogle Scholar5. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006;45:721-4. [PMID: 16819252] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, and National Cancer Centre Singapore, Singapore 169610.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByGlomerular Diseases Associated with Hepatitis B and C Infection, AdultGlomerular Diseases Associated with Hepatitis B and C Infection, AdultRisk of Reverse Seroconversion of Hepatitis B Virus Surface Antigen in Rituximab-Treated Non-Hodgkin Lymphoma PatientsB Lymphocytes Are Required during the Early Priming of CD4 + T Cells for Clearance of Pneumocystis Infection in MiceReactivación del virus de la hepatitis B en pacientes tratados con rituximab: incidencia y factores de riesgoManagement of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapyAnti-CD20 monoclonal antibodies: Beyond B-cellsRituximab-induced direct inhibition of T-cell activationRituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsAn Argument for the Universal Prophylaxis of Hepatitis B Infection in Patients Receiving Rituximab: A 7‐Year Institutional Experience of Hepatitis ScreeningHBV disease: HBsAg carrier and occult B infection reactivation in haematological settingDoes rituximab increase the incidence of infectious complications? A narrative reviewTreatment of Hepatitis B Virus-Associated NephropathyPreventing Hepatitis B reactivation in immunosuppressed patients: Is it time to revisit the guidelines?Rheumatic manifestations of hepatitisCurrent awareness: Pharmacoepidemiology and drug safety 5 May 2009Volume 150, Issue 9Page: 655-656KeywordsAntigensCancer treatmentChemotherapyDNAHepatitis BHepatitis B virusLymph nodesLymphocytesLymphomaProphylaxis ePublished: 5 May 2009 Issue Published: 5 May 2009 CopyrightCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...